Human Papillomavirus Circulating Tumor DNA Assays As a Mechanism for Head and Neck Cancer Equity in Rural Regions of the United States

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 May 23

PMID 38779091

Authors

Melina Windon

Catherine Haring

Affiliations

Soon will be listed here.

Abstract

The rates of human papillomavirus-positive oropharyngeal cancer (HPV-OPC) are rising worldwide and in the United States, particularly in rural regions including Appalachia. Rural areas face unique health challenges resulting in higher cancer incidence and mortality rates, and this includes HPV-OPC. The recent advent of highly sensitive liquid biopsies for the non-invasive detection of HPV-OPC recurrence (circulating tumor HPV DNA, HPV ctDNA) has been swiftly adopted as part of surveillance paradigms. Though knowledge gaps persist regarding its use and clinical trials are ongoing, the ease of collection and cost-effectiveness of HPV ctDNA make it more accessible for HPV-OPC survivors than usual surveillance methods of frequent exams and imaging. Herein, we discuss how implementing HPV ctDNA assays in rural regions of the United States provide one poignant example of how liquid biopsies can improve cancer care equity.

References

Guo T, Qualliotine J, Ha P, Califano J, Kim Y, Saunders J . Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer. 2015; 121(12):1977-84. PMC: 4457566. DOI: 10.1002/cncr.29323. View

Haring C, Kana L, Dermody S, Brummel C, McHugh J, Casper K . Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer. 2023; 129(18):2817-2827. DOI: 10.1002/cncr.34823. View

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

Beeler W, Bellile E, Casper K, Jaworski E, Burger N, Malloy K . Patient-reported financial toxicity and adverse medical consequences in head and neck cancer. Oral Oncol. 2019; 101:104521. PMC: 7008081. DOI: 10.1016/j.oraloncology.2019.104521. View

Naegele S, Ruiz-Torres D, Zhao Y, Goss D, Faden D . Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers. J Mol Diagn. 2023; 26(3):179-190. PMC: 10918646. DOI: 10.1016/j.jmoldx.2023.11.007. View

Rulach R, Zhou S, Hendry F, Stobo D, James A, Dempsey M . 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers. Oral Oncol. 2019; 97:76-81. DOI: 10.1016/j.oraloncology.2019.08.011. View

Ward M, Riaz N, Caudell J, Dunlap N, Isrow D, Zakem S . Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys. 2017; 100(3):586-594. PMC: 9131594. DOI: 10.1016/j.ijrobp.2017.06.012. View

Batool S, Sethi R, Wang A, Dabekaussen K, Egloff A, Del Vecchio Fitz C . Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study. Oral Oncol. 2023; 147:106584. DOI: 10.1016/j.oraloncology.2023.106584. View

DSouza G, Tewari S, Troy T, Waterboer T, Struijk L, Castillo R . Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023; 129(15):2373-2384. PMC: 10330354. DOI: 10.1002/cncr.34783. View

10.

Kumar B, Cipolla M, Old M, Brown N, Kang S, Dziegielewski P . Surgical management of oropharyngeal squamous cell carcinoma: Survival and functional outcomes. Head Neck. 2015; 38 Suppl 1:E1794-802. DOI: 10.1002/hed.24319. View

11.

Ahn S, Chan J, Zhang Z, Wang H, Khan Z, Bishop J . Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014; 140(9):846-54. PMC: 4313904. DOI: 10.1001/jamaoto.2014.1338. View

12.

Chera B, Kumar S, Beaty B, Marron D, Jefferys S, Green R . Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res. 2019; 25(15):4682-4690. PMC: 6679766. DOI: 10.1158/1078-0432.CCR-19-0211. View

13.

Szilagyi P, Albertin C, Gurfinkel D, Saville A, Vangala S, Rice J . Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US. Vaccine. 2020; 38(38):6027-6037. PMC: 9495911. DOI: 10.1016/j.vaccine.2020.06.074. View

14.

Gunning A, Kumar S, Williams C, Berger B, Naber S, Gupta P . Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers. Diagnostics (Basel). 2023; 13(4). PMC: 9955790. DOI: 10.3390/diagnostics13040725. View

15.

Zhang L, Freeman T, Sun S, Bhateja P, Cloyd J, Rocco J . The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma. Oral Oncol. 2023; 139:106357. DOI: 10.1016/j.oraloncology.2023.106357. View

16.

Vanderpool R, Dressler E, Stradtman L, Crosby R . Fatalistic beliefs and completion of the HPV vaccination series among a sample of young Appalachian Kentucky women. J Rural Health. 2015; 31(2):199-205. PMC: 4753791. DOI: 10.1111/jrh.12102. View

17.

Bhambhani C, Sandford E, Haring C, Brummel C, Tuck K, Olesnavich M . Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma. Oral Oncol. 2023; 143:106436. DOI: 10.1016/j.oraloncology.2023.106436. View

18.

Hudson L, Burus T, Park L, Huang B, Hull P, Vanderford N . Cancer disparities in Appalachian Kentucky. J Rural Health. 2023; 40(1):87-95. PMC: 10593907. DOI: 10.1111/jrh.12763. View

19.

Eytan D, Blackford A, Eisele D, Fakhry C . Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States. Cancer. 2018; 125(2):249-260. DOI: 10.1002/cncr.31800. View

20.

Guo F, Adekanmbi V, Hsu C, Berenson A . Incidence of human papillomavirus-related cancers among males and females aged 15-34 years in the United States. JNCI Cancer Spectr. 2023; 7(2). PMC: 10029840. DOI: 10.1093/jncics/pkad016. View